FDA Brief

Warning letters Drugs

FDA warning letter to

Dr Retter Ec Wladyslaw Retter

High riskIssued Mar 14, 2022Posted Mar 29, 2022Center for Drug Evaluation and Research | CDER

FDA warns Dr Retter Ec Wladyslaw Retter over manufacturing failures for homeopathic drug cream.

What happened

FDA reviewed records the firm submitted after a June 2, 2021, request for records; no inspection dates are given. FDA found no process validation data for a homeopathic cream and a label concentration that was about 4 C different from the batch record—about 100,000,000 times the active concentration. It also found no specific identity test for incoming components, incomplete batch records, and inadequate microbial specifications.

What FDA found

  1. The firm lacked adequate written production and process control procedures and did not follow them; its homeopathic cream was distributed without process validation, and the label's dilution did not match the batch record by about 4 C.

    21 CFR 211.100(a) and (b)
  2. The firm did not conduct at least one specific identity test for each component lot, relying instead on organoleptic examination or the supplier's certificate of analysis.

    21 CFR 211.84(d)(1)
  3. Batch production and control records did not document significant steps, including equipment identity, step durations, total batch duration, and who performed each step.

    21 CFR 211.188(b)
  4. Laboratory controls lacked scientifically sound microbial specifications; the COA did not show total aerobic microbial count testing per USP <61> and had no justification for the yeast and mold limit.

    21 CFR 211.160(b)

What FDA wants

FDA asks the firm to respond in writing within 15 working days describing corrections and prevention, including validation, component identity testing, batch records, and lab controls; if actions cannot be completed, give reasons and a schedule. FDA also strongly recommends a qualified CGMP consultant.

Who should pay attention

  • U.S. distributors and brands importing OTC or homeopathic drugs from Poland
  • contract manufacturers and suppliers of homeopathic drug products
  • quality teams handling process validation, component identity testing, and microbial testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk